Stockscreener 앱 받기
3.78
0.38%
-0.05
전일 마감가:
$3.83
열려 있는:
$3.79
하루 거래량:
11,689
Relative Volume:
0.09
시가총액:
$4.93M
수익:
$10.48M
순이익/손실:
$-37.74M
주가수익비율:
-0.2336
EPS:
-16.1846
순현금흐름:
$-29.03M
1주 성능:
-6.02%
1개월 성능:
-42.19%
6개월 성능:
-84.25%
1년 성능:
-95.89%
1일 변동 폭
$3.77
$3.83
1주일 범위
$3.71
$4.0706
52주 변동 폭
$3.71
$110.75
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
3.78 | 4.93M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.99 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.00 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.31 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
580.42 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
271.58 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study - marketscreener.com
First Study Site Established for Jaguar Health Study of its FDA - GuruFocus
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Canine Treatment | JAGX Stock News - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | JAGX Stock News - GuruFocus
First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman
Jaguar Health Reports First Quarter 2025 Financials - The Columbus Dispatch
Jaguar Health Provides Update on Meeting with FDA Discussing Sta - GuruFocus
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer By Investing.com - Investing.com South Africa
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Akron Beacon Journal
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health to Reveal Critical FDA Feedback on Breakthrough Phase 3 Breast Cancer Trial Results - Stock Titan
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | - GuruFocus
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | JAGX Stock News - GuruFocus
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - The Columbus Dispatch
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer - Investing.com
Breakthrough: FDA Meeting Could Fast-Track New Breast Cancer Treatment Following Positive Trial Data - Stock Titan
Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates - ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - Detroit Free Press
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health CEO to Reveal New Orphan Drug Development Strategy: Key Updates Coming June 10 - Stock Titan
Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th - ACCESS Newswire
Knight Therapeutics and Jaguar Health Announce Strategic Partnership - ACCESS Newswire
Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Columbus Dispatch
Jaguar Health (NASDAQ:JAGX) Upgraded at Wall Street Zen - Defense World
Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer - ACCESS Newswire
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ - MSN
Jaguar Health Announces $1.5M Direct Stock Offering - TipRanks
Jaguar Health prices 0.25M shares at $6.09 in registered direct offering - MSN
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ By Stocktwits - Investing.com India
Jaguar Health announces $1.5 million direct offering By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
0.26%
자본화:
|
볼륨(24시간):